Merck takes over Ariad's ridaforolimus under amended deal
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals and Merck & Co are restructuring their collaboration for the development and commercialisation of ridaforolimus, Ariad's investigational mTOR inhibitor.